Replication competent oncolytic group b adenovirus

A replication competent oncolytic group B adenovirus EnAd comprising: two or more transgenes, a first transgene comprising a DNA sequence encoding B7-1 protein, and an additional transgene encoding an anti-CD3 antibody or binding fragment thereof, pharmaceutical compositions comprising said virus an...

Full description

Saved in:
Bibliographic Details
Main Authors BRIAN ROBERT CHAMPION, ALICE CLAIRE NOEL BROMLEY
Format Patent
LanguageEnglish
Hebrew
Published 01.07.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A replication competent oncolytic group B adenovirus EnAd comprising: two or more transgenes, a first transgene comprising a DNA sequence encoding B7-1 protein, and an additional transgene encoding an anti-CD3 antibody or binding fragment thereof, pharmaceutical compositions comprising said virus and use of any one of the same in treatment, in particular the treatment of cancer.
Bibliography:Application Number: IL20210284375